AI-generated content for informational purposes only. Not financial advice. Always do your own research.

Over

Anglo-Zweeds farmaceutisch bedrijf en een van 's werelds grootste geneesmiddelenfabrikanten. Toonaangevende pijplijn in oncologie, cardiovasculaire en respiratoire therapieën.

Europese blue chips

AstraZeneca is een van Europas grootste farmaceutische bedrijven, met robuuste portefeuilles voor oncologie en respiratoire geneesmiddelen en een toonaangevende R&D-pijplijn.

Farmaceutische Aandelen

AstraZeneca is een wereldwijd farmaceutisch leider met een sterke pijplijn in oncologie, cardiovasculaire en respiratoire therapieën, die consistent groei boven de industriestandaard levert.

Key Financials AZN

Prijs $205.55
Wijziging (1D) +0.50%
Wijziging (30D) +123.59%
Wijziging (60D) +129.92%
Wijziging (90D) +140.44%
Wijziging (180D) +192.06%
Wijziging (1Y) +176.17%
Wijziging (5Y) +307.76%
P/E-verhouding 34.55
EPS (TTM) $5.95
52-weekse bandbreedte $61.24 — $206.71
50-daags MA $120.02
Volume 2.50M

Data updated Feb 15 · Source: Twelve Data

4.5
1 reviews
Market Leadership
4.8
Innovation Capability
4.7
Brand Reputation
4.7
Financial Stability
4.2
Governance & Ethics
4
Claude Opus 4.6
AI Review
4.5/5

AstraZeneca has established itself as one of the world's premier biopharmaceutical companies, with a robust oncology pipeline that drives much of its growth narrative. The stock has delivered extraordinary performance, trading near its 52-week high of $206.71 with remarkable gains across all timeframes " up over 176% year-over-year and 308% over five years.

The bull case centers on AZN's industry-leading oncology franchise (Tagrisso, Imfinzi, Enhertu), expanding rare disease portfolio via the Alexion acquisition, and consistent revenue growth. Management has targeted $80 billion in revenue by 2030, an ambitious but credible goal given pipeline depth.

However, the bear case warrants attention. The P/E ratio of 34.55 is elevated for a large-cap pharma, pricing in significant future growth. Key patent expirations loom in the late 2020s, and the recent price surge may leave limited near-term upside. Regulatory and pricing pressures across global markets remain persistent headwinds.

AstraZeneca is a high-quality pharmaceutical holding, though current valuations suggest investors should consider entry points carefully. The pipeline strength and diversification provide a solid long-term foundation.

Market Leadership
4.8
Brand Reputation
4.7
Innovation Capability
4.7
Financial Stability
4.2
Governance & Ethics
4
Feb 15, 2026
AstraZeneca Screenshot

Added: Feb 15, 2026

astrazeneca.com

Latest from Otrai